Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Exp Toxicol Pathol ; 64(1-2): 9-14, 2012 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-20579860

RESUMEN

Plants from the genus Piper are economically useful and some species have been indicated because of their medicinal properties in the central nervous system. However, few studies about toxicity and neurobehavioral effects have been conducted. In this study, two Piper species, P. amalago and P. mikanianum were investigated in rats to determine acute toxicity and to evaluate the ansiogenic/ansiolytic properties in the elevated plus-maze and the effects on locomotion and exploration in an open field. Additionally, genotoxic activities were evaluated, using the comet assay in several tissues and the micronucleus assay in bone marrow. The phytochemical analysis of both Piper species leaves suggests the presence of amide, essential oils, flavonoids and phenolic compounds. The LD(50) of P. amalago and P. mikanianum were estimated as 2,545 and 1,661 mg/kg, respectively. The behavioral and genotoxic parameters were determined after an intraperitoneal administration of P. amalago (250 or 420 mg/kg) or P. mikanianum (160 or 270 mg/kg). Both plants decreased the number of entries and time spent in the open arms in the plus-maze test, indicating an anxiogenic effect. Only P. mikanianum affected locomotion and exploration in the open field behavior test. No genotoxic or mutagenic effect was observed. Our results suggest that these Piper species act on the central nervous system, without induce genetic toxicity.


Asunto(s)
Conducta Animal/efectos de los fármacos , Encéfalo/efectos de los fármacos , Daño del ADN , Piper/química , Extractos Vegetales/toxicidad , Animales , Médula Ósea/efectos de los fármacos , Encéfalo/patología , Ensayo Cometa , Relación Dosis-Respuesta a Droga , Conducta Exploratoria/efectos de los fármacos , Inyecciones Intraperitoneales , Dosificación Letal Mediana , Hígado/efectos de los fármacos , Hígado/patología , Masculino , Aprendizaje por Laberinto/efectos de los fármacos , Micronúcleos con Defecto Cromosómico/inducido químicamente , Pruebas de Micronúcleos , Extractos Vegetales/aislamiento & purificación , Hojas de la Planta/química , Plantas Medicinales , Ratas , Ratas Wistar , Pruebas de Toxicidad Aguda
2.
Can J Physiol Pharmacol ; 84(12): 1239-44, 2006 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-17487231

RESUMEN

Sibutramine has been described as an anti-obesity drug with the ability to inhibit serotonin (5-HT), noradrenaline, and dopamine re-uptake, but without affinity to histamine and muscarinic receptors. On the other hand, cyproheptadine antagonizes serotonin 5-HT(2A), 5-HT(2B), and 5-HT(2C), histamine H1, and muscarinic (M) receptors. There are many reports concerning the influence of sibutramine on central serotoninergic pathways. In this study, we suggest that peripheral pathways may also be involved in the serotoninergic effects of sibutramine. In vivo experiments were undertaken to investigate the serotoninergic effects of sibutramine on body mass, the glycogen concentration in the diaphragm of rats, and locomotor behaviour. Rats were submitted to oral treatment with sibutramine, cyproheptadine, or sibutramine applied in combination with cyproheptadine, for a period of 2 months to investigate the 5-HT2 effects of sibutramine on these parameters. As the results demonstrated, the lower increase in body mass and the increased glycogen levels in the diaphragm muscle of rats treated with sibutramine seem to be modulated by 5-HT2 receptors, since these effects were completely antagonized by cyproheptadine in the group treated with the 2 drugs co-applied. Furthermore, the behavioural results also suggest that mechanisms modulated by 5-HT2 receptors are involved in the increase of locomotion in the rats treated with sibutramine, since the effect did not occur in the rats treated with sibutramine co-applied with the 5-HT2 receptor antagonist, cyproheptadine. The results suggest that sibutramine modifies energy-related parameters such as body mass, diaphragm glycogen, and locomotor behaviour in rats via 5-HT2 serotoninergic pathways.


Asunto(s)
Depresores del Apetito/farmacología , Ciclobutanos/farmacología , Actividad Motora/efectos de los fármacos , Receptores de Serotonina 5-HT2/efectos de los fármacos , Inhibidores Selectivos de la Recaptación de Serotonina/farmacología , Animales , Peso Corporal/efectos de los fármacos , Ciproheptadina/farmacología , Diafragma/efectos de los fármacos , Diafragma/metabolismo , Ingestión de Alimentos/efectos de los fármacos , Metabolismo Energético/efectos de los fármacos , Glucógeno/metabolismo , Masculino , Ratas , Ratas Wistar , Antagonistas de la Serotonina/farmacología , Factores de Tiempo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA